De Quervain disease (DQVD) is one of the most common causes of lateral wrist pain and can lead to significant disability. The current case involves a right-handed, middle-aged, female patient with severe lateral wrist pain due to DQVD. Her pain was not responsive to oral non-steroidal anti-inflammatory drugs, rehabilitation, and repeated corticosteroid injections. Because she refused surgical intervention, we performed ultrasound-guided methotrexate injections (four times). After the injections, dramatic pain relief, functional improvement, and reduction of the thickness of the retinaculum and tendons in the first dorsal extensor compartment of the wrist were noted. This case report highlights the potential usefulness of ultrasound-guided methotrexate injection for recalcitrant DQVD of the wrist.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627726PMC
http://dx.doi.org/10.2147/JPR.S143256DOI Listing

Publication Analysis

Top Keywords

ultrasound-guided methotrexate
12
methotrexate injection
8
quervain disease
8
lateral wrist
8
wrist pain
8
wrist
5
injection quervain
4
disease wrist
4
wrist lies
4
lies horizon?
4

Similar Publications

Uterine artery embolization plus ultrasound guided curettage for cesarean scar pregnancy: Five-year experience at a single tertiary hospital.

Taiwan J Obstet Gynecol

January 2025

Department of Gynecology & Obstetrics, Beijing friendship hospital, Capital Medical University, No. 95, Yong'an Road, Xi-cheng district, Beijing, China. Electronic address:

Objective: To study immediate therapeutic outcomes, subsequent fertility effects and menstrual changes in cesarean scar pregnancy patients who received uterine artery embolization with or without methotrexate followed by ultrasound guided curettage.

Materials And Methods: Totally, 82 patients who met the inclusion criteria were enrolled in our study and divided into two groups. Group I included 50 patients who received uterine artery embolization and ultrasound guided curettage, and Group II had 32 patients who received uterine artery embolization plus methotrexate and ultrasound guided curettage.

View Article and Find Full Text PDF

Local and systemic methotrexate in management of caesarean scar pregnancy.

Eur J Obstet Gynecol Reprod Biol

February 2025

Department of Gynecology and Obstetrics, CHU de Bicêtre, AP-HP, DMU2, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France; University Paris-Saclay, 63, rue Gabriel-Péri, 94270 Le Kremlin-Bicêtre, France; University Paris-Saclay, UVSQ, INRAE, BREED, 78350 Jouy-en-Josas, France. Electronic address:

Study Objective: The aim is to analyze the management of cesarean scar pregnancy (CSP) based on local and systemic Methotrexate, a protocol implemented in a referral center.

Design: This is an observational, retrospective, monocentric, cohort study with a description of the local protocol, treatment results and tolerance profile. Design Classification III.

View Article and Find Full Text PDF

Introduction: Intramural ectopic pregnancy (IMP) refers to the implantation and implantation of a gestational sac in the uterine muscle layer, which is a rare and potentially life-threatening disease. Early detection and diagnosis are significant, and treatment methods are often challenging.

Presentation Of Case: We report a case of IMP after embryo transfer in a 38-year-old woman.

View Article and Find Full Text PDF

: Caesarean scar pregnancy (CSP) is a rare form of ectopic pregnancy in which the early pregnancy implants at the site of the uterine scar. Methotrexate (MTX) in lower doses can be used to treat CSPs. However, MTX administration is associated with a spectrum of side effects that include hematological toxicities.

View Article and Find Full Text PDF

Renal medullary carcinoma is a rare, high-grade carcinoma arising in the renal medulla, which is usually associated with sickle cell trait, and there are very few documented cases in the Japanese population. We report a case of renal medullary carcinoma, immunohistochemically defined as SMARCB1 deficient, in a 67-year-old Japanese woman without a history of sickle cell trait. Somatic mutation of SMARCB1 and an EML4::ALK fusion gene were identified by comprehensive genomic profiling.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!